Arvinas (ARVN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
24 Jun, 2026Opening remarks and agenda
Meeting called to order in an all-virtual format to facilitate global participation.
Introductions made for executive officers, board members, legal counsel, election inspector, and auditors.
Rules of conduct for participation and Q&A outlined at the start.
Corporate governance
Notice of meeting and proxy statement confirmed as sent to all stockholders of record.
Quorum established with 79.24% of shares represented, allowing business to proceed.
Overview of voting outcomes
Election of Class II directors Leslie Norwalk and Randy Teel approved.
Advisory vote on executive compensation passed.
Ratification of Deloitte & Touche LLP as auditor confirmed.
Final voting results to be filed in Form 8-K within four business days.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Arvinas
- FDA approval and out-licensing of VEPPANU drove record Q2 revenue and net income.ARVN
Q2 2026 - Phase III vepdegestrant data and new combination results are set to drive multiple launches and pipeline growth.ARVN
2024 Cantor Fitzgerald Global Healthcare Conference - First PROTAC approval, focused pipeline, and key clinical milestones ahead in PSP and SBMA.ARVN
Jefferies Global Healthcare Conference 2026 - FDA approved VEPPANU, the first PROTAC degrader, amid Q1 net loss and strong cash reserves.ARVN
Q1 2026 - Shareholders will vote on directors, executive pay, and auditor ratification, with strong governance and ESG focus.ARVN
Proxy filing - Votes will be held on director elections, executive pay, and auditor ratification at the 2026 meeting.ARVN
Proxy filing - Improved financials and pipeline progress set stage for key 2026 milestones and FDA review.ARVN
Q4 2025 - Vepdegestrant improved median PFS by 2.9 months over fulvestrant in ESR1-mutant breast cancer.ARVN
Study Update - Q1 2025 saw revenue and net income surge, with restructuring extending cash runway into 2H 2028.ARVN
Q1 2025